Latest News

• 
  All Medical News

  EHA 2018: UK real-world outcomes in NDMM

  Written by Alex Burton | 1 May 2019

  Faouzi Djebbari (Oxford) also gives his thoughts on the unmet needs of the newly diagnosed MM patient who is ineligble for stem cell transplantation.

• 
  All Medical News

  Translational science in IBD

  Written by Karen Ramirez | 9 Apr 2019

  Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.

• 
  All Medical News

  IBD around the world

  Written by Karen Ramirez | 9 Apr 2019

  IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…

• 
  All Medical News

  Metabolic profiling

  Written by Karen Ramirez | 13 Mar 2019

  Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to… read more.

• 
  All Medical News

  VARSITY: head to head comparison of adalimumab vs vedolizumab in UC

  Written by Karen Ramirez | 13 Mar 2019

  The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab…. read more.

• 
  All Medical News

  ECCO 2019 highlights

  Written by Karen Ramirez | 11 Mar 2019

  The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.

• 
  All Medical News

  Highlights from ASH 2018

  Written by Karen Ramirez | 14 Feb 2019

  As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study,… read more.

• 
  All Medical News

  ASH 2018: Advances in the management of peripheral T-cell lymphoma

  Written by Karen Ramirez | 5 Feb 2019

  Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.

• 
  All Medical News

  ASH 2018: Phoenix and other DLBCL study updates

  Written by Karen Ramirez | 5 Feb 2019

  Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.

• 
  All Medical News

  ASH 2018: Advances in RRMM

  Written by Alex Burton | 25 Jan 2019

  Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.

• 
  All Medical News

  ASH 2018: TOURMALINE-MM3 study

  Written by Alex Burton | 25 Jan 2019

  Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.

• 
  All Medical News

  ASH 2018: Novel agents in combination for relapsed/refractory Hodgkin’s lymphoma: the ECOG-ACRIN E4412 study

  Written by Alex Burton | 14 Jan 2019

  Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.